Evidence map›Paper›PMID 40632872›Full record

ArticleScience advances2025

The human genetic variant rs6190 unveils Foxc1 and Arid5a as novel prometabolic targets of the glucocorticoid receptor in muscle.

Ashok Daniel Prabakaran, Fabian Montecino-Morales, Kevin McFarland, Thirupugal Govindarajan, Hima Bindu Durumutla, Hannah Latimer, Olukunle Akinborewa, Chiara Villa, Douglas P Millay, Mattia Quattrocelli

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Ashok Daniel PrabakaranMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0001-9053-2673
Fabian Montecino-MoralesMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Kevin McFarlandMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Thirupugal GovindarajanMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0003-2660-9730
Hima Bindu DurumutlaMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Hannah LatimerMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0009-0000-2233-2485
Olukunle AkinborewaMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0002-6735-4802
Chiara VillaMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0002-3002-3372
Douglas P MillayMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0001-5188-0720
Mattia QuattrocelliMolecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0001-7011-1740

Funding

Coordinated mechanisms to rescue bioenergetics and sarcopenia in agingR01AG078174 · NIA · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2022 to 2025
$1.3M
Harnessing novel glucocorticoid biology to treat diabetic cardiomyopathyR01HL166356 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2023 to 2025
$1.2M
ROLE OF CIRCADIAN RHYTHM AND INTERMITTENT DOSING IN MUSCLE TRIGLYCERIDE LIPASE INDUCTION BY GLUCOCORTICOIDSR03DK130908 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI QUATTROCELLI, MATTIA · 2022 to 2023
$249k
NHLBI NIH HHS R01 HL166356NIA NIH HHS R01 AG078174NIDDK NIH HHS R03 DK130908
6 · The paper itself

Abstract

The mechanisms segregating positive from negative effects of the glucocorticoid receptor (GR) on metabolic health remain poorly elucidated. Here, we generated mice genocopying the human GR polymorphism rs6190, which was sufficient to increase muscle insulin sensitivity and blunt obesity-induced adverse effects on adiposity and exercise intolerance. We identified

Indexed as

DNA-Binding ProteinsForkhead Transcription FactorsMuscle, SkeletalPolymorphism, Single NucleotideReceptors, GlucocorticoidTranscription FactorsAnimalsGene Expression RegulationHumansInsulin ResistanceMaleMiceSignal TransductionDNA-Binding ProteinsForkhead Transcription FactorsFOXC1 protein, humanReceptors, GlucocorticoidTranscription Factors

Identifiers

PMID40632872
PMCPMC12239956

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.